| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
|
N Engl J Med
|
2006
|
8.26
|
|
2
|
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
|
Blood
|
2002
|
4.00
|
|
3
|
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
|
Blood
|
2002
|
3.60
|
|
4
|
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.
|
Blood
|
2012
|
3.38
|
|
5
|
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
|
Blood
|
2010
|
3.15
|
|
6
|
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
|
Proc Natl Acad Sci U S A
|
2006
|
3.06
|
|
7
|
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
|
N Engl J Med
|
2015
|
3.00
|
|
8
|
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
|
Blood
|
2004
|
2.77
|
|
9
|
Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study.
|
Lancet
|
2002
|
2.33
|
|
10
|
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
|
Blood
|
2006
|
2.15
|
|
11
|
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
|
Blood
|
2007
|
2.05
|
|
12
|
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
|
Am J Hematol
|
2010
|
1.66
|
|
13
|
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
|
Blood
|
2007
|
1.62
|
|
14
|
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
|
Blood
|
2003
|
1.50
|
|
15
|
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
|
Cancer
|
2005
|
1.38
|
|
16
|
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
|
Blood
|
2005
|
1.32
|
|
17
|
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
|
Clin Cancer Res
|
2003
|
1.29
|
|
18
|
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.
|
Br J Haematol
|
2009
|
1.28
|
|
19
|
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
|
Blood
|
2003
|
1.23
|
|
20
|
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.
|
Blood
|
2002
|
1.20
|
|
21
|
Treatment of patients with advanced cancer with the natural killer cell line NK-92.
|
Cytotherapy
|
2013
|
1.17
|
|
22
|
Transcriptional profiling of human hematopoiesis during in vitro lineage-specific differentiation.
|
Stem Cells
|
2005
|
1.11
|
|
23
|
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
|
Blood
|
2003
|
1.11
|
|
24
|
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
|
Haematologica
|
2008
|
1.08
|
|
25
|
Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis.
|
Transfusion
|
2007
|
1.04
|
|
26
|
Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors.
|
Exp Hematol
|
2009
|
1.02
|
|
27
|
Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
|
Cancer Res
|
2007
|
1.02
|
|
28
|
Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.
|
Exp Hematol
|
2005
|
1.02
|
|
29
|
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
|
PLoS One
|
2013
|
1.02
|
|
30
|
Decitabine and vitamin D3 differentially affect hematopoietic transcription factors to induce monocytic differentiation.
|
Int J Oncol
|
2007
|
0.96
|
|
31
|
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
|
Blood
|
2010
|
0.96
|
|
32
|
Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.
|
Haematologica
|
2004
|
0.94
|
|
33
|
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
|
Cancer
|
2007
|
0.92
|
|
34
|
Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia.
|
Haematologica
|
2007
|
0.88
|
|
35
|
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
|
Eur J Clin Pharmacol
|
2012
|
0.88
|
|
36
|
Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Semin Hematol
|
2002
|
0.87
|
|
37
|
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
|
Br J Haematol
|
2013
|
0.87
|
|
38
|
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
|
Haematologica
|
2014
|
0.87
|
|
39
|
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR.
|
Haematologica
|
2007
|
0.87
|
|
40
|
The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
|
BMC Cancer
|
2009
|
0.86
|
|
41
|
A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies.
|
Leuk Res
|
2013
|
0.86
|
|
42
|
Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement.
|
Cancer Genet Cytogenet
|
2008
|
0.86
|
|
43
|
Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia.
|
Leuk Lymphoma
|
2004
|
0.85
|
|
44
|
p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.
|
Haematologica
|
2011
|
0.85
|
|
45
|
Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.
|
Blood
|
2003
|
0.84
|
|
46
|
FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment.
|
Blood
|
2005
|
0.84
|
|
47
|
Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.
|
Int J Hematol
|
2004
|
0.84
|
|
48
|
Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid.
|
Clin Epigenetics
|
2011
|
0.84
|
|
49
|
Expression of interleukin-18 receptor in fibroblast-like synoviocytes.
|
Arthritis Res
|
2001
|
0.83
|
|
50
|
Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
|
Oncogene
|
2003
|
0.83
|
|
51
|
p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.
|
Cancer Sci
|
2004
|
0.82
|
|
52
|
Regulation of human IL-18 gene expression: interaction of PU.1 with GC-box binding protein is involved in human IL-18 expression in myeloid cells.
|
Eur J Immunol
|
2004
|
0.82
|
|
53
|
Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).
|
Blood
|
2002
|
0.81
|
|
54
|
Inhibition of HIV-1 replication by small interfering RNAs directed against glioma pathogenesis related protein (GliPR) expression.
|
Retrovirology
|
2010
|
0.80
|
|
55
|
Polo-like kinases in AML.
|
Expert Opin Investig Drugs
|
2012
|
0.80
|
|
56
|
Comparison of TaqMan real-time PCR and p24 Elisa for quantification of in vitro HIV-1 replication.
|
J Virol Methods
|
2003
|
0.80
|
|
57
|
Characterization of ZC3H15 as a potential TRAF-2-interacting protein implicated in the NFκB pathway and overexpressed in AML.
|
Int J Oncol
|
2013
|
0.79
|
|
58
|
Identification of defects in the transcriptional program during lineage-specific in vitro differentiation of CD34(+) cells selected from patients with both low- and high-risk myelodysplastic syndrome.
|
Exp Hematol
|
2010
|
0.78
|
|
59
|
Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients.
|
Cancer Lett
|
2011
|
0.78
|
|
60
|
Folinic acid antagonizes methotrexate-induced differentiation of monocyte progenitors.
|
Rheumatol Int
|
2002
|
0.78
|
|
61
|
Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth.
|
Br J Haematol
|
2005
|
0.78
|
|
62
|
Endoplasmic reticulum protein GliPR1 regulates G protein signaling and the cell cycle and is overexpressed in AML.
|
Oncol Rep
|
2013
|
0.78
|
|
63
|
Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms.
|
Leuk Res
|
2004
|
0.77
|
|
64
|
Methodologic and biological variability of quantitative real-time polymerase chain reaction analysis of Bcr-Abl expression in Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Haematologica
|
2003
|
0.77
|
|
65
|
Coordination of cell growth in cocultures by a genetic proliferation control system.
|
Biotechnol Bioeng
|
2002
|
0.77
|
|
66
|
The DAC system and associations with acute leukemias and myelodysplastic syndromes.
|
Invest New Drugs
|
2010
|
0.77
|
|
67
|
Knockdown of ERM family member moesin in host cells increases HIV type 1 replication.
|
AIDS Res Hum Retroviruses
|
2011
|
0.76
|
|
68
|
HIV-1 infection suppresses expression of host cell cycle-associated gene PDS5A.
|
Intervirology
|
2011
|
0.76
|
|
69
|
Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia.
|
Ann Hematol
|
2013
|
0.76
|
|
70
|
Inhibition of X4-tropic HIV type 1 replication by knockdown of the cellular protein LEREPO4.
|
AIDS Res Hum Retroviruses
|
2010
|
0.75
|